Protalix BioTherapeutics, Inc. (PLX)
Chart Events
Performance Outlook
| Previous Close | 3.1800 |
| Open | 3.1400 |
| Bid | 3.0300 x 1800 |
| Ask | 3.0400 x 1200 |
| Day's Range | 3.0000 - 3.1500 |
| 52 Week Range | 2.8100 - 7.0200 |
| Volume | 422,481 |
| Avg. Volume | 1,630,329 |
| Market Cap | 137.056M |
| Beta (5Y Monthly) | 2.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2240 |
| Earnings Date | May 31, 2021 - Jun 04, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
Fair Value
Related Research
- PR Newswire
Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the first quarter 2021 and business update on Friday, May 14, 2021. The Company's management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30 a.m. Eastern Daylight Time (EDT).
- Zacks Small Cap Research
PLX: Pandemic Backup Impedes FDA Site Survey
John Vandermosten, CFA NYSE:PLX Following the anticipated April 27 th target action date for its investigational candidate, Protalix Biotherapeutics, Inc. (NYSE:PLX) announced that the FDA had issued a Complete Response Letter (CRL) related to the submission of PRX-102. 1 Protalix and Chiesi Global Rare Disease submitted the Biologics License Application (BLA) for the PEGylated enzyme and
- ACCESSWIRE
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Protalix BioTherapeutics, Inc. (PLX) Investigation
NEW YORK, NY / ACCESSWIRE / April 28, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Protalix BioTherapeutics, Inc. ("Protalix" or "the Company") (NYSE:PLX).
